Projected Earnings Date: 2025-11-04    (Delayed quote data   2025-09-12)
Last
 46.55
Change
 ⇑ +0.31   (+0.67%)
Volume
  3,632,245
Open
 46.56
High
 47.04
Low
 45.19
8EMA (Daily)
 42.36
40EMA (Daily)
 38.79
50EMA (Daily)
 38.63
STO (Daily)
 92.578
MACD Hist (Daily)
 1.898
8EMA (Weekly)
 39.882
40EMA (Weekly)
 39.74
50EMA (Weekly)
 39.72
STO (Weekly)
 56.041
MACD Hist (Weekly)
 1.643
Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products include RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio, and SOS1 and 4EBP1/mTORC1 programs.
optionchance optionchance
Home | Chart and Research | Education | About Us  

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.

Questions or Comments: support@optionchance.com
Copyright © 2025 OptionChance.com